CommercialCoverageMedium impact
State and School Employees' Health Insurance Plan - Chimeric Antigen Receptor Therapy for Leukemia and Lymphoma
Blue Cross & Blue Shield of Mississippi·Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new comprehensive medical policy for State and School Employees' Health Insurance Plan covering CAR T-cell therapy for leukemia and lymphoma. The policy establishes coverage criteria for five FDA-approved CAR T-cell products (Aucatzyl, Breyanzi, Kymriah, Tecartus, Yescarta) used to treat specific blood cancers including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma.
Action Required
Immediately: Review complete policy document to understand coverage criteria and prior authorization requirements for CAR T-cell therapy treatments. Oncology and hematology billing staff should familiarize themselves with the five covered products (Aucatzyl, Breyanzi, Kymriah, Tecartus, Yescarta) and their approved indications for leukemia and lymphoma patients under State and School Employees' Health Insurance Plan.